A retrospective review of treatment and response of high-risk mast cell tumours in dogs

• Published in: Veterinary & comparative oncology 2016-12, Vol.14 (4), p.361-370
• Main Authors: Miller, R. L., Van Lelyveld, S., Warland, J., Dobson, J. M., Foale, R. D.
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; canine; chemotherapy; Chemotherapy, Adjuvant - veterinary; Dog Diseases - drug therapy; Dog Diseases - mortality; Dog Diseases - surgery; Dogs; masitinib; Mastocytoma - drug therapy; Mastocytoma - mortality; Mastocytoma - surgery; Mastocytoma - veterinary; metastasis; Neoplasm Grading; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Risk Factors; surgery; Survival Analysis; Thiazoles - therapeutic use; Treatment Outcome; tyrosine kinase; vinblastine
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12116

This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients were treated with a cytotoxic chemotherapy protocol or the tyrosine kinase inhibitor masitinib, in the presence of gross disease or as an adjunct to surgical resection of the primary tumour. In patients presenting with metastatic disease, surgical resection of the primary tumour with adjunctive therapy with any chemotherapy incurred a significant survival advantage [median survival time (MST): 278 days] compared to patients receiving chemotherapy without surgical excision of the primary tumour (MST: 91 days, P < 0.0001). Patients with a surgically excised Patnaik grade II tumour and high Ki‐67 in the absence of metastatic disease treated with vinblastine and prednisolone showed a significantly longer survival (MST: 1946 days) than those treated with masitinib (MST: 369 days, P = 0.0037). Further prospective case‐controlled clinical trials of high‐risk MCTs are required to make precise evidence‐based treatment decisions for individual patients.